Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386501654> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- W4386501654 abstract "The objective of this study was to investigate whether apoC3 (apolipoprotein C3) inhibition with an antisense oligonucleotide (ASO) modulates intestinal triglyceride secretion.Sprague-Dawley rats were treated with subcutaneous injections of apoC3 ASO 25 mg/kg twice weekly or inactive ASO for 4 weeks before the assessment of lymph flow, triglyceride and apoB48 appearance in the lymph. Rats were surgically implanted with catheters in the mesenteric lymph duct and duodenum. Following an overnight fast, an intraduodenal lipid bolus (1.5-mL intralipid) was administered. Lymph fluid was collected for the following 4 hours to compare effects on lymph flow, lymph triglyceride and apoB48 concentration, and secretion. To assess suppression of apoC3 expression and protein abundance by apoC3 ASO compared with inactive ASO (placebo), intestinal and hepatic tissues were collected from a subset of animals before (fasting) and after an enteral lipid bolus (post-lipid).ApoC3 ASO significantly reduced apoC3 mRNA expression in the liver compared with inactive ASO (fasting: 42%, P=0.0048; post-lipid: 66%, P<0.001) and in the duodenum (fasting: 29%, P=0.0424; post-lipid: 53%, P=0.0120). As expected, plasma triglyceride also decreased significantly (fasting: 74%, P<0.001; post-lipid: 33%, P=0.0276). Lymph flow and cumulative lymph volume remained unchanged following apoC3 ASO therapy; however, lymph triglyceride, but not apoB48 output, increased by 38% (ANOVA, P<0.001). Last, no changes were observed in stool triglyceride, intestinal fat (quantified via oil red O staining), and expression of mRNAs involved in triglyceride synthesis, lipid droplet formation, and chylomicron transport and secretion.Despite the marked reduction in plasma triglyceride concentration that occurs with apoC3 ASO inhibition, intestinal triglyceride output surprisingly increased rather than decreased. These data demonstrate that the reduction of intestinal triglyceride output does not contribute to the potent plasma triglyceride-lowering observed with this novel therapy for hypertriglyceridemia. Further studies are required to explore the mechanism of this intestinal effect." @default.
- W4386501654 created "2023-09-08" @default.
- W4386501654 creator A5010857613 @default.
- W4386501654 creator A5034414826 @default.
- W4386501654 creator A5087753070 @default.
- W4386501654 date "2023-09-07" @default.
- W4386501654 modified "2023-09-28" @default.
- W4386501654 title "Unanticipated Enhancement of Intestinal TG Output by Apoc3 ASO Inhibition" @default.
- W4386501654 doi "https://doi.org/10.1161/atvbaha.123.319765" @default.
- W4386501654 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37675633" @default.
- W4386501654 hasPublicationYear "2023" @default.
- W4386501654 type Work @default.
- W4386501654 citedByCount "0" @default.
- W4386501654 crossrefType "journal-article" @default.
- W4386501654 hasAuthorship W4386501654A5010857613 @default.
- W4386501654 hasAuthorship W4386501654A5034414826 @default.
- W4386501654 hasAuthorship W4386501654A5087753070 @default.
- W4386501654 hasConcept C126322002 @default.
- W4386501654 hasConcept C134018914 @default.
- W4386501654 hasConcept C142724271 @default.
- W4386501654 hasConcept C185592680 @default.
- W4386501654 hasConcept C2778163477 @default.
- W4386501654 hasConcept C2778913445 @default.
- W4386501654 hasConcept C2779237934 @default.
- W4386501654 hasConcept C2779720271 @default.
- W4386501654 hasConcept C2780931953 @default.
- W4386501654 hasConcept C43376680 @default.
- W4386501654 hasConcept C71924100 @default.
- W4386501654 hasConceptScore W4386501654C126322002 @default.
- W4386501654 hasConceptScore W4386501654C134018914 @default.
- W4386501654 hasConceptScore W4386501654C142724271 @default.
- W4386501654 hasConceptScore W4386501654C185592680 @default.
- W4386501654 hasConceptScore W4386501654C2778163477 @default.
- W4386501654 hasConceptScore W4386501654C2778913445 @default.
- W4386501654 hasConceptScore W4386501654C2779237934 @default.
- W4386501654 hasConceptScore W4386501654C2779720271 @default.
- W4386501654 hasConceptScore W4386501654C2780931953 @default.
- W4386501654 hasConceptScore W4386501654C43376680 @default.
- W4386501654 hasConceptScore W4386501654C71924100 @default.
- W4386501654 hasLocation W43865016541 @default.
- W4386501654 hasLocation W43865016542 @default.
- W4386501654 hasOpenAccess W4386501654 @default.
- W4386501654 hasPrimaryLocation W43865016541 @default.
- W4386501654 hasRelatedWork W1969808273 @default.
- W4386501654 hasRelatedWork W1993873099 @default.
- W4386501654 hasRelatedWork W2013998010 @default.
- W4386501654 hasRelatedWork W2023333646 @default.
- W4386501654 hasRelatedWork W2028937980 @default.
- W4386501654 hasRelatedWork W2035484352 @default.
- W4386501654 hasRelatedWork W2162912823 @default.
- W4386501654 hasRelatedWork W2350174576 @default.
- W4386501654 hasRelatedWork W2418447797 @default.
- W4386501654 hasRelatedWork W2748952813 @default.
- W4386501654 isParatext "false" @default.
- W4386501654 isRetracted "false" @default.
- W4386501654 workType "article" @default.